ISIS Pharmaceuticals forms $65M partnership with AstraZeneca

By partnering with the British drug manufacturer, AstraZeneca, ISIS Pharmaceuticals intends to expand their “antisense” technology into drugs targeting cardiovascular, metabolic and kidney diseases more quickly and efficiently. Essentially, AstraZeneca is providing additional funding as well as the clinical expertise that will allow ISIS to further their development, testing and fine tuning of genetic therapies for these diseases without compromising any current projects.

As one of the many world-changing companies in Carlsbad’s burgeoning life sciences cluster, ISIS Pharmaceuticals is changing the way patients receive healthcare. Click here for the full article.